Irinotecan-Cetuximab-Bevacizumab as a Salvage Treatment in Heavily Pretreated Metastatic Colorectal Cancer Patients: A Retrospective Observational Study

Publisher： Karger

E-ISSN： 1421-9794|57|2|138-144

ISSN： 0009-3157

Source： Chemotherapy, Vol.57, Iss.2, 2011-03, pp. : 138-144

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

By  

Chemotherapy, Vol. 56, Iss. 2, 2010-04 ,pp. : 142-146

Karger

Access to resources Recommend Favorite

Sequential Treatment with Irinotecan and Doxifluridine: Optimal Dosing Schedule in Murine Models and in a Phase I Study for Metastatic Colorectal Cancer

By  

Chemotherapy, Vol. 51, Iss. 1, 2005-04 ,pp. : 32-39

Karger

Access to resources Recommend Favorite

Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment

By  

Chemotherapy, Vol. 62, Iss. 1, 2016-09 ,pp. : 80-84

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Modified FOLFOX6 plus High-Dose Bevacizumab in Second-Line or Later Treatment of Patients with Metastatic Colorectal Cancer

By  

Chemotherapy, Vol. 59, Iss. 2, 2013-07 ,pp. : 79-84

Karger

Access to resources Recommend Favorite

Antibiotic Treatment in End-of-Life Cancer Patients—A Retrospective Observational Study at a Palliative Care Center in Sweden

By Helde-Frankling Maria   Bergqvist Jenny   Bergman Peter   Björkhem-Bergman Linda  

Cancers, Vol. 8, Iss. 9, 2016-09 ,pp. : 84-84

MDPI

Access to resources Recommend Favorite